Market Overview

UPDATE: Wedbush Reiterates Cardica at Outperform on Key Milestone, Financing Catalyst

Related CRDC
Medtronic's Cardiac Monitor Boosts AF Detection in Stroke Patients - Analyst Blog
Allscripts Healthcare's Sunrise EHR Platform Expansion on Track - Analyst Blog

Wedbush maintained its Outperform rating and $5 price target on Cardica (NASDAQ: CRDC).

Wedbush said, "Cardica announced that it made its first shipment of the XCHANGE30 MicroCutter stapler to its European distributer for Germany, Austria and Switzerland. In our view, this announcement represents a significant milestone for Cardica as it signals that the company has finally moved beyond the iterative design process that was holding back the device's commercial introduction earlier this year. … With a commercially-ready device now in hand, we expect Cardica to focus on its near-term financing needs. We anticipate a raise of approximately $15 million occurring towards the beginning of next year, which would extend Cardica's cash runway by roughly 12 months. We view the completion of a financing as an important near-term catalyst for investors."

Cardica closed at $1.01 on Wednesday.

Latest Ratings for CRDC

DateFirmActionFromTo
Nov 2014Craig-HallumDowngradesBuyHold
May 2013WedbushInitiates Coverage onOutperform
Jan 2013Loewen, Ondaatje, McCutcheon USA LimitedInitiates Coverage onBuy

View More Analyst Ratings for CRDC
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (CRDC)

Around the Web, We're Loving...

Get Benzinga's Newsletters